No cases progressed from LTBI to active TB, which may support the effectiveness of current screening and prophylaxis strategies in our country.<h4>What is known</h4>• TNF-α inhibitors are associated with an increased risk of developing active tuberculosis (TB) disease as a result of the reactivation of latent TB infection (LTBI).<h4>What is new</h4>• Screening for LTBI at initiation and during TNF-α inhibitor treatment, along with appropriate LTBI prophylaxis, prevented LTBI reactivation into active TB disease in BCG-vaccinated patients receiving TNF-α inhibitors. This evidence concerns the gene TNF and tuberculosis.